|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/15/20 Cell MedX Corp. 10-Q 8/31/20 51:1.9M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 271K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 15K
12: R1 Document and Entity Information HTML 63K
13: R2 Condensed Consolidated Balance Sheets HTML 82K
14: R3 Condensed Consolidated Balance Sheets - HTML 22K
Parenthetical
15: R4 Condensed Consolidated Statements of Operations HTML 71K
16: R5 Condensed Consolidated Statement of Stockholders' HTML 57K
Deficit
17: R6 Condensed Consolidated Statements of Cash Flows HTML 82K
18: R7 Organization and Nature of Operations HTML 21K
19: R8 Related Party Transactions Disclosure HTML 29K
20: R9 Inventory Disclosure HTML 18K
21: R10 Other Current Assets Disclosure HTML 17K
22: R11 Equipment Disclosure HTML 22K
23: R12 Revenue Disclosure HTML 22K
24: R13 Notes and Advances Payable Disclosure HTML 36K
25: R14 Share Capital Disclosure HTML 37K
26: R15 Related Party Transactions Disclosure: Schedule of HTML 23K
Amounts Due to Related Parties (Tables)
27: R16 Related Party Transactions Disclosure: Schedule of HTML 21K
Transactions with Related Parties (Tables)
28: R17 Equipment Disclosure: Change in book value of the HTML 22K
equipment (Tables)
29: R18 Revenue Disclosure: Schedule of Revenue and HTML 22K
Associated Costs (Tables)
30: R19 Notes and Advances Payable Disclosure: Schedule of HTML 31K
Short-term Loans and Advances Outstanding (Tables)
31: R20 Share Capital Disclosure: Schedule of Stock Option HTML 24K
Activity (Tables)
32: R21 Share Capital Disclosure: Schedule of Stock HTML 22K
Options Outstanding (Tables)
33: R22 Share Capital Disclosure: Schedule of Warrant HTML 20K
Activity (Tables)
34: R23 Share Capital Disclosure: Schedule of Warrant HTML 23K
Details (Tables)
35: R24 Organization and Nature of Operations (Details) HTML 19K
36: R25 Related Party Transactions Disclosure: Schedule of HTML 31K
Amounts Due to Related Parties (Details)
37: R26 Related Party Transactions Disclosure: Schedule of HTML 24K
Transactions with Related Parties (Details)
38: R27 Inventory Disclosure (Details) HTML 20K
39: R28 Other Current Assets Disclosure (Details) HTML 19K
40: R29 Equipment Disclosure: Change in book value of the HTML 25K
equipment (Details)
41: R30 Revenue Disclosure: Schedule of Revenue and HTML 33K
Associated Costs (Details)
42: R31 Notes and Advances Payable Disclosure: Schedule of HTML 40K
Short-term Loans and Advances Outstanding
(Details)
43: R32 Notes and Advances Payable Disclosure (Details) HTML 30K
44: R33 Share Capital Disclosure (Details) HTML 31K
45: R34 Share Capital Disclosure: Schedule of Stock Option HTML 26K
Activity (Details)
46: R35 Share Capital Disclosure: Schedule of Stock HTML 29K
Options Outstanding (Details)
47: R36 Share Capital Disclosure: Schedule of Warrant HTML 22K
Activity (Details)
48: R37 Share Capital Disclosure: Schedule of Warrant HTML 37K
Details (Details)
50: XML IDEA XML File -- Filing Summary XML 88K
49: EXCEL IDEA Workbook of Financial Reports XLSX 43K
6: EX-101.INS XBRL Instance -- cmxc-20200831 XML 492K
8: EX-101.CAL XBRL Calculations -- cmxc-20200831_cal XML 60K
9: EX-101.DEF XBRL Definitions -- cmxc-20200831_def XML 234K
10: EX-101.LAB XBRL Labels -- cmxc-20200831_lab XML 429K
11: EX-101.PRE XBRL Presentations -- cmxc-20200831_pre XML 369K
7: EX-101.SCH XBRL Schema -- cmxc-20200831 XSD 98K
51: ZIP XBRL Zipped Folder -- 0001393905-20-000301-xbrl Zip 49K
| ex-31.1 |
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Frank McEnulty, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending August 31, 2020, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 15, 2020
/s/ Frank McEnulty
Chief Executive Officer
(Principal Executive Officer)
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/15/20 | |||
| For Period end: | 8/31/20 | NT 10-K | ||
| List all Filings | ||||